Buy or sell Regeneron Pharmaceuticals stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
Regeneron Pharmaceuticals Stock
Regeneron Pharmaceuticals is focused on the development of pharmaceutical products for the treatment of serious medical conditions.
About Regeneron Pharmaceuticals Stock
Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.
Vice President, Head, Regeneron Genetics Center
Manager, Combination Products Engineering
Executive Vice President, Research and Development
Senior Vice President, Regulatory Affairs
Senior Vice President, Human Resources
Senior Staff Engineer, Bioreactor Scale-Up and Development
Senior Director, Business Development
Founder, President, and Chief Executive Officer
Leonard S. Schleifer
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase